C&L: Dr. Rahul Singhvi tapped to run Novavax

Dr. Rahul Singhvi has been appointed president and CEO of Novavax. Prior to joining Novavax in 2004, Dr. Singhvi had 11 years of experience in the pharmaceutical industry, including serving as a director within the manufacturing division of Merck.

Michael S. Paul, PhD, has been promoted to president of LineaGen Research. Dr. Paul will continue to hold the position of COO. Stephen M. Prescott, MD, who previously held the titles of president and CEO, will continue to serve as LineaGen's CEO.

Richard G. Babbitt, chairman of the board of directors of Lipid Sciences, died unexpectedly on August 6. Babbitt was 79.

David R. Parkinson, MD, formerly vice president and head of global clinical oncology at Amgen, will assume a new role as vice president, oncology development and commercialization.

Genmab has named Bo Kruse as vice president and interim CFO. Kruse was formerly Genmab's vice president finance and chief accounting officer.

Wang Bingyu has been hired as the vice president, sales and marketing of Beijing Med-Pharm. Wang most recently spent five years as director, sales and marketing for Sino-American Beijing HuaJin Pharmaceuticals.

Germany's Merck announced that Thad Evans will join the company on October 1, 2005, and will succeed Joachim Szebel as head of the Pigments Division on January 1, 2006. Szebel, 61, has been with Merck for 33 years and will retire at the end of 2005.

Phyton Biotech has added three scientists to its team: Michael Horn, PhD, Sarad Parekh, PhD, and Guillermo Tous, PhD.

Dendrite International has named Peter Ladell and Peter Tombros to the company's board of directors.

Gemin X Biotechnologies named Timothy J. Barberich and Wayne I. Roe to its board of directors.

Jenne K. Britell, PhD, has been elected to Quest Diagnostics board of directors.

Amarin has appointed Dr. Prem Lachman as non-executive director.

Seattle Genetics has added Richard A. Flavell, PhD, to its scientific advisory board.

Suggested Articles

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

Scientists have discovered a scorpion toxin could inspire treatments to block the inflammation that triggers chronic pain.

The phase 2 success keeps Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.